Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?
Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor (PPAR)-γ agonists commonly used as insulin-sensitizing drugs for the treatment of type 2 diabetes. In the last decade, PPAR-γ agonists have received increasing attention for their neuroprotective properties displayed in a varie...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Parkinson's Disease |
| Online Access: | http://dx.doi.org/10.4061/2011/689181 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832552351736528896 |
|---|---|
| author | Anna R. Carta Augusta Pisanu Ezio Carboni |
| author_facet | Anna R. Carta Augusta Pisanu Ezio Carboni |
| author_sort | Anna R. Carta |
| collection | DOAJ |
| description | Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor (PPAR)-γ agonists commonly used as insulin-sensitizing drugs for the treatment of type 2 diabetes. In the last decade, PPAR-γ agonists have received increasing attention for their neuroprotective properties displayed in a variety of neurodegenerative diseases, including Parkinson's disease (PD), likely related to the anti-infammatory activity of these compounds. Recent studies indicate that neuroinflammation, specifically reactive microglia, plays important roles in PD pathogenesis. Moreover, after the discovery of infiltrating activated Limphocytes in the substantia nigra (SN) of PD patients, most recent research supports a role of immune-mediated mechanisms in the pathological process leading to chronic neuroinflammation and dopaminergic degeneration. PPAR-γ are highly expressed in cells of both central and peripheral immune systems, playing a pivotal role in microglial activation as well as in monocytes and T cells differentiation, in which they act as key regulators of immune responses.
Here, we review preclinical evidences of PPAR-γ-induced neuroprotection in experimental PD models and highlight relative anti-inflammatory mechanisms involving either central or peripheral immunomodulatory activity. Specific targeting of immune functions contributing to neuroinflammation either directly (central) or indirectly (peripheral) may represent a novel therapeutic approach for disease modifying therapies in PD. |
| format | Article |
| id | doaj-art-47b1a529b0074eeb8cb09b53d02b2b6c |
| institution | Kabale University |
| issn | 2042-0080 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Parkinson's Disease |
| spelling | doaj-art-47b1a529b0074eeb8cb09b53d02b2b6c2025-02-03T05:58:51ZengWileyParkinson's Disease2042-00802011-01-01201110.4061/2011/689181689181Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?Anna R. Carta0Augusta Pisanu1Ezio Carboni2Department of Toxicology, University of Cagliari, Via Ospedale 72, 09124 Cagliari, ItalyDepartment of Toxicology, University of Cagliari, Via Ospedale 72, 09124 Cagliari, ItalyDepartment of Toxicology, University of Cagliari, Via Ospedale 72, 09124 Cagliari, ItalyThiazolidinediones (TZDs) are peroxisome proliferator-activated receptor (PPAR)-γ agonists commonly used as insulin-sensitizing drugs for the treatment of type 2 diabetes. In the last decade, PPAR-γ agonists have received increasing attention for their neuroprotective properties displayed in a variety of neurodegenerative diseases, including Parkinson's disease (PD), likely related to the anti-infammatory activity of these compounds. Recent studies indicate that neuroinflammation, specifically reactive microglia, plays important roles in PD pathogenesis. Moreover, after the discovery of infiltrating activated Limphocytes in the substantia nigra (SN) of PD patients, most recent research supports a role of immune-mediated mechanisms in the pathological process leading to chronic neuroinflammation and dopaminergic degeneration. PPAR-γ are highly expressed in cells of both central and peripheral immune systems, playing a pivotal role in microglial activation as well as in monocytes and T cells differentiation, in which they act as key regulators of immune responses. Here, we review preclinical evidences of PPAR-γ-induced neuroprotection in experimental PD models and highlight relative anti-inflammatory mechanisms involving either central or peripheral immunomodulatory activity. Specific targeting of immune functions contributing to neuroinflammation either directly (central) or indirectly (peripheral) may represent a novel therapeutic approach for disease modifying therapies in PD.http://dx.doi.org/10.4061/2011/689181 |
| spellingShingle | Anna R. Carta Augusta Pisanu Ezio Carboni Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy? Parkinson's Disease |
| title | Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy? |
| title_full | Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy? |
| title_fullStr | Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy? |
| title_full_unstemmed | Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy? |
| title_short | Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy? |
| title_sort | do ppar gamma agonists have a future in parkinson s disease therapy |
| url | http://dx.doi.org/10.4061/2011/689181 |
| work_keys_str_mv | AT annarcarta doppargammaagonistshaveafutureinparkinsonsdiseasetherapy AT augustapisanu doppargammaagonistshaveafutureinparkinsonsdiseasetherapy AT eziocarboni doppargammaagonistshaveafutureinparkinsonsdiseasetherapy |